JPWO2023196545A5 - - Google Patents
Info
- Publication number
- JPWO2023196545A5 JPWO2023196545A5 JP2024559031A JP2024559031A JPWO2023196545A5 JP WO2023196545 A5 JPWO2023196545 A5 JP WO2023196545A5 JP 2024559031 A JP2024559031 A JP 2024559031A JP 2024559031 A JP2024559031 A JP 2024559031A JP WO2023196545 A5 JPWO2023196545 A5 JP WO2023196545A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- standard
- comprises administration
- care
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263329010P | 2022-04-08 | 2022-04-08 | |
| US63/329,010 | 2022-04-08 | ||
| US202263345736P | 2022-05-25 | 2022-05-25 | |
| US63/345,736 | 2022-05-25 | ||
| PCT/US2023/017805 WO2023196545A1 (en) | 2022-04-08 | 2023-04-07 | Cancer treatments using mta-cooperative prmt5 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025511399A JP2025511399A (ja) | 2025-04-15 |
| JPWO2023196545A5 true JPWO2023196545A5 (https=) | 2025-07-28 |
| JP2025511399A5 JP2025511399A5 (https=) | 2025-07-28 |
Family
ID=86328467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024559031A Pending JP2025511399A (ja) | 2022-04-08 | 2023-04-07 | Ｍｔａ協同的ｐｒｍｔ５阻害剤を使用する癌の処置 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250228861A1 (https=) |
| EP (1) | EP4504199A1 (https=) |
| JP (1) | JP2025511399A (https=) |
| KR (1) | KR20240169712A (https=) |
| CN (1) | CN119317435A (https=) |
| AU (1) | AU2023249277A1 (https=) |
| CA (1) | CA3255376A1 (https=) |
| CL (1) | CL2024003040A1 (https=) |
| IL (1) | IL315996A (https=) |
| JO (1) | JOP20240223A1 (https=) |
| MX (1) | MX2024012431A (https=) |
| TW (1) | TW202345844A (https=) |
| WO (1) | WO2023196545A1 (https=) |
| ZA (1) | ZA202407596B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202440126A (zh) * | 2022-11-30 | 2024-10-16 | 美商安進公司 | 利用ｍｔａ協作的ｐｒｍｔ５抑制劑和ｍａｔ２ａ抑制劑之癌症治療 |
| EP4637774A1 (en) * | 2022-12-21 | 2025-10-29 | Amgen Inc. | Cancer treatments using mta-cooperative prmt5 inhibitors |
| AU2024356380A1 (en) * | 2023-10-06 | 2026-04-02 | Amgen Inc. | Cancer treatments using mta-cooperative prmt5 inhibitors |
| TW202519223A (zh) * | 2023-10-31 | 2025-05-16 | 大陸商康百達（四川）生物醫藥科技有限公司 | 一種吡啶衍生物及其在醫藥上的應用 |
| WO2025098450A1 (zh) * | 2023-11-08 | 2025-05-15 | 北京泰德制药股份有限公司 | Prmt5抑制剂及其制备方法 |
| WO2025113703A1 (zh) * | 2023-12-01 | 2025-06-05 | 上海翰森生物医药科技有限公司 | 四并环类衍生物抑制剂、其制备方法和应用 |
| WO2025157284A1 (zh) * | 2024-01-26 | 2025-07-31 | 上海湃隆生物科技有限公司 | 包含prmt5抑制剂和化疗剂的药物组合物 |
| WO2025157287A1 (zh) * | 2024-01-26 | 2025-07-31 | 上海湃隆生物科技有限公司 | 包含prmt5抑制剂和egfr抑制剂的药物组合物 |
| WO2025176054A1 (zh) * | 2024-02-20 | 2025-08-28 | 华润医药研究院（深圳）有限公司 | 三环杂环类化合物及其制备方法和医药用途 |
| WO2025194059A1 (en) * | 2024-03-15 | 2025-09-18 | Prelude Therapeutics Incorporated | Combination treatment regimens - smarca2 degrader with taxane anticancer agent |
| WO2025207705A1 (en) * | 2024-03-26 | 2025-10-02 | Amgen Inc. | Cancer treatments using mta-cooperative prmt5 inhibitors |
| WO2025213154A1 (en) * | 2024-04-05 | 2025-10-09 | Amgen Inc. | Gastrointestinal cancer treatments using mta-cooperative prmt5 inhibitors |
| WO2025250569A1 (en) * | 2024-05-29 | 2025-12-04 | Amgen Inc. | Cancer treatments using mta-cooperative prmt5 inhibitors and mat2a inhibitors |
| WO2025265110A1 (en) * | 2024-06-21 | 2025-12-26 | Amgen Inc. | Oral pharmaceutical compositions comprising a naphthyridine compound |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3129832A1 (en) * | 2019-02-13 | 2020-08-20 | Les Laboratoires Servier | Combination therapies for use in treating cancer |
| JP7787819B2 (ja) * | 2020-02-12 | 2025-12-17 | アムジェン インコーポレイテッド | 新規ｐｒｍｔ５阻害剤 |
| AU2021400942A1 (en) * | 2020-12-16 | 2023-07-06 | Amgen Inc. | PRMT5 inhibitors |
-
2023
- 2023-04-07 CA CA3255376A patent/CA3255376A1/en active Pending
- 2023-04-07 EP EP23721498.6A patent/EP4504199A1/en active Pending
- 2023-04-07 IL IL315996A patent/IL315996A/en unknown
- 2023-04-07 TW TW112113091A patent/TW202345844A/zh unknown
- 2023-04-07 WO PCT/US2023/017805 patent/WO2023196545A1/en not_active Ceased
- 2023-04-07 AU AU2023249277A patent/AU2023249277A1/en active Pending
- 2023-04-07 KR KR1020247037062A patent/KR20240169712A/ko active Pending
- 2023-04-07 CN CN202380045230.7A patent/CN119317435A/zh active Pending
- 2023-04-07 US US18/853,736 patent/US20250228861A1/en active Pending
- 2023-04-07 JP JP2024559031A patent/JP2025511399A/ja active Pending
-
2024
- 2024-10-06 JO JOJO/P/2024/0223A patent/JOP20240223A1/ar unknown
- 2024-10-07 ZA ZA2024/07596A patent/ZA202407596B/en unknown
- 2024-10-07 MX MX2024012431A patent/MX2024012431A/es unknown
- 2024-10-08 CL CL2024003040A patent/CL2024003040A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2023196545A5 (https=) | ||
| de Bree et al. | Pharmacological principles of intraperitoneal and bidirectional chemotherapy | |
| Goodman et al. | Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy | |
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| CN100363004C (zh) | 喹唑啉衍生物zd6474组合吉西他滨在制备药物中的用途 | |
| Markman | Intraperitoneal chemotherapy in the management of malignant disease | |
| Hamai et al. | Results of neoadjuvant chemoradiotherapy with docetaxel and 5-fluorouracil followed by esophagectomy to treat locally advanced esophageal cancer | |
| Wang et al. | Concurrent neoadjuvant chemoradiotherapy for Siewert II and III adenocarcinoma at gastroesophageal junction | |
| JPWO2022269525A5 (https=) | ||
| Tewes et al. | Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study | |
| Mühr-Wilkenshoff et al. | A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma | |
| JP2009536956A (ja) | 抗癌治療法 | |
| Tsimafeyeu et al. | Cholangiocarcinoma: an emerging target for molecular therapy | |
| Font et al. | Weekly docetaxel with concomitant radiotherapy in patients with inoperable oesophageal cancer | |
| US20170112807A1 (en) | Combination chemotherapy comprising a liposomal prodrug of mitomycin c | |
| Eskander et al. | Intraperitoneal chemotherapy from Armstrong to HIPEC: challenges and promise | |
| Vokes et al. | Adjuvant and neoadjuvant treatments for NSCLC | |
| Sasamoto et al. | Long-term results of chemoradiotherapy for locally advanced esophageal cancer, using daily low-dose 5-fluorouracil and cis-diammine-dichloro-platinum (CDDP) | |
| JP2020520385A5 (https=) | ||
| Murphy | Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck | |
| JPWO2022260132A5 (https=) | ||
| JPWO2023059795A5 (https=) | ||
| Al-Sarraf | The role of concurrent chemo-radiotherapy in patients with head and neck cancers: a review | |
| Kohno | The role of chemotherapy for advanced oro and hypopharyngeal cancer | |
| JP2020533368A5 (https=) |